Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

Schneck, Dennis W.; Knopp, Robert H.; Ballantyne, Christie M.; McPherson, Ruth; Chitra, Rohini; Simonson, Steven G.

doi:10.1016/s0002-9149(02)02994-6

Cited by 130 publications

(71 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, no muscle or liver safety concerns were observed during rosuvastatin treatment. This is consistent with similar safety findings reported in other studies on rosuvastatin 16,18,[21][22][23] . There have been concerns that increased plasma levels of rosuvastatin in Asians, as shown in single-dose pharmacokinetic studies, may lead to increased adverse drug effects 10) .…”

Section: Discussionsupporting

confidence: 93%

Effects of Rosuvastatin on Low-Density Lipoprotein Cholesterol and Plasma Lipids in Asian Patients with Hypercholesterolemia

Tan

Low

Lim

et al. 2009

JAT

View full text Add to dashboard Cite

Aims:Rosuvastatin is more efficacious than other statins in lowering low-density lipoprotein cholesterol (LDL-C). Studies showing higher blood levels in Asians have resulted in concerns regarding increased adverse drug reactions. This study aimed to evaluate the efficacy and safety of rosuvastatin in hypercholesterolemic Asian patients. Methods: This retrospective observational study was conducted on statin-naive patients and statinswitch patients. Patients were treated with rosuvastatin for ≥ 8 weeks. Primary outcomes were changes in LDL-C levels and proportions of patients achieving their goals (primary prevention, LDL-C ≤ 130 mg/dL; secondary prevention, LDL-C ≤ 100 mg/dL). Results: Of 1007 hypercholesterolemic patients, 483 were statin-naive (LDL-C 161 40.8 mg/dL) and 524 were statin-switch patients (LDL-C 132.7 36.9 mg/dL). In statin-naive patients, rosuvastatin significantly reduced LDL-C, total cholesterol, and triglycerides by 39.9%, 28.8%, and 9.2%, respectively (p 0.001). Eighty-one percent of these patients achieved LDL-C goals. In the statinswitch cohort, LDL-C, total cholesterol, and triglycerides levels were significantly reduced by 24.5%, 16.6%, and 3.8%, respectively (p 0.001). Achievement of target LDL-C levels increased from 29% to 72.9%. There was no significant adverse drug reaction. Conclusion

show abstract

Section: Discussionsupporting

confidence: 93%

Effects of Rosuvastatin on Low-Density Lipoprotein Cholesterol and Plasma Lipids in Asian Patients with Hypercholesterolemia

Tan

Low

Lim

et al. 2009

JAT

View full text Add to dashboard Cite

show abstract

“…Reduction in triglycerides and increase in HDL-C were observed at both dose levels, with no dose-response effect being observed. Our results are consistent with previously reported for rosuvastatin treatment (18,19). Treatment with rosuvastatin 40 mg/day produced greater improvement in LDL-C and total cholesterol than rosuvastatin 10 mg/day; however, as expected, both treatments had equal beneficial effects for HDL-C and triglycerides.…”

Section: Discussionsupporting

confidence: 93%

Effect of Rosuvastatin on ROCK Activity, Endothelial Function, and Inflammation in Asian Patients with Atherosclerosis

et al. 2012

View full text Add to dashboard Cite

Background HMG-CoA reductase inhibitors (statins) inhibit cholesterol biosynthesis, and also decrease the formation of isoprenoid intermediates required for the activation of Rho kinase (ROCK) pathway. ROCK pathway plays pivotal roles in cardiovascular diseases including arteriosclerosis. It has been implicated that inhibition of ROCK can reverse vascular dysfunction in humans with atherosclerosis. However, it is not clear whether statins, at doses used to lower cholesterol levels, inhibit ROCK activity in humans with atherosclerosis. Methods We treated 40 subjects with stable atherosclerosis with rosuvastatin 10 mg/day, or rosuvastatin 40 mg/day for 28 days in a randomized, double-blinded study. We assessed the change in the lipid levels, Creactive protein (CRP), ROCK activity, and flow-mediated dilation (FMD) of the brachial artery before and after statins therapy. Results Treatment with rosuvastatin 10 mg and 40 mg significantly reduced LDL cholesterol by 43.2% to 55.9% and increased FMD by 29.3% to 42.5% (p<0.05 for both compared with baselines). Both doses inhibited ROCK activity (p<0.05), and the extent of inhibition was greater with rosuvastatin 40 mg compared with 10 mg (p<0.05). Only rosuvastatin 40 mg significantly reduced hsCRP (p<0.05).There was no correlation between changes in ROCK activity and changes in low-density lipoprotein cholesterol (r=0.37, p>0.05 vs. r= 0.41, p>0.05) among patients randomized to rosuvastatin 10 mg group or 40 mg group. There was a correlation between ROCK inhibition and change in FMD among patients with rosuvastatin 10 mg therapy (r=0.43, p<0.05), and 40 mg therapy (r=0.54, p<0.05). Correlation was found between changes in ROCK inhibition and changes in CRP in rosuvastatin 40 mg/day group (r=0.47, p<0.05). Conclusion These results demonstrate that high dose rosuvastatin exerts greater effects on LDL-C, ROCK activity, and CRP than low dose rosuvastatin. These findings provide clinical evidence that statins are effective in improving endothelium dysfunction by a cholesterol-independent mechanism in patients with atherosclerosis.

show abstract

“…18 A similar comparative study done by Schneck et al, on 374 hypercholesterolemia patients without active arterial disease showed that Rosuvastatin was significantly effective in compared to Atorvastatin in maintaining lipid profile which is similar with the result of my study. 19 Davidson et al, in the study of 516 North American population found that Rosuvastatin 5mg/day in compared to Atorvastatin 10mg/day were associated with greater in LDL-C, reduction and HDL-C increase which is similar with the result of my study. 20 Reduction in the TC and TG did not match with result of my study of 3 months periods.…”

Section: Discussionsupporting

confidence: 86%

A comparative study of atorvastatin and rosuvastatin in dyslipidemia

Thapa¹,

Rai²,

Mahara³

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

INTRODUCTIONWorldwide, hypercholesterolemia cause about 56% of ischemic heart disease and 18% of strokes, resulting to 4.4 million deaths annually. Hyperlipidemia and the rates of hypercholesterolemia (total cholesterol ≥201.1mg/dl) increased from 18% to 31% in adults aged 35-59. 1 Studies have shown that the risk of ischemic heart disease in individuals with hypercholesterolemia is about thrice as great as in those with normal plasma cholesterol level indicating that reduction in plasma cholesterol does reduce the risk of myocardial infraction. 2There is increasing evidence that Hyperlipidemia is a major cause of atherosclerosis and atherosclerosisassociated conditions, such as coronary heart disease (CHD), ischemic cerebrovascular disease and peripheral vascular disease and reduction of TC and LDL-C below 442.86mg/dl and 116mg/dl, respectively, lowers the incidence of CHD. The lifetime risk of developing CHD after 40 years of age is 49% in men and 32% in women. Even at 70 years of age, the risk is 35% for men and 24% for women. 3 The lifetime risk of developing CVD at 50 years of age is estimated to be 1 in 2 for men and 2 in 5 for women in USA only. 4 Numerous epidemiologic investigations have suggested that age, sex, elevated LDL-ABSTRACT Background: To compare the drugs: Atorvastatin (10mg) and Rosuvastatin (5mg) in patients with Dyslipidemia.Methods: This open-label, randomized, parallel group, comparative, prospective study of six months duration included 100 patients. The age group of patients varied from 30 to 69 years with dyslipidemia. Patients were divided in to 2 groups. 50 patients in group-1 received Atorvastatin 10mg once daily and 50 patients in group-2 received Rosuvastatin 5 mg once daily. The level of TC, TG, LDL, VLDL and HDL were assessed at baseline and at the end of 3 months and 6 months. Results: At 3 months, LDL was reduced significantly more with 5mg Rosuvastatin than with Atorvastatin 10 mg [43.68% vs. 40.74% (P 0.0049)]. At 6 months, Rosuvastatin 5mg reduced LDL significantly more than Atorvastatin 10 mg [48.69% vs. 43.85% (P 0.00)]. TC, HDL, TG and VLDL were more favourably modified by Rosuvastatin at 6 months (P <0.005). Reduction of total cholesterol levels in Rosuvastatin group was not statistically significant when compared with Atorvastatin group (P 0.103). Conclusions: Rosuvastatin 5mg was more efficacious than Atorvastatin 10mg for the improvement of lipid profile during the period of 6 months follow-up drug therapy in patients with dyslipidemia.

show abstract

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

Cited by 130 publications

References 16 publications

Effects of Rosuvastatin on Low-Density Lipoprotein Cholesterol and Plasma Lipids in Asian Patients with Hypercholesterolemia

Effects of Rosuvastatin on Low-Density Lipoprotein Cholesterol and Plasma Lipids in Asian Patients with Hypercholesterolemia

Effect of Rosuvastatin on ROCK Activity, Endothelial Function, and Inflammation in Asian Patients with Atherosclerosis

A comparative study of atorvastatin and rosuvastatin in dyslipidemia

Contact Info

Product

Resources

About